JSJianlong Song

Jianlong Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jianlong Song has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Chunrong Tao

    Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China

    4 shared publications
  • Jun Sun

    Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China

    4 shared publications
  • Mohamad Abdalkader

    Boston Medical Center

    4 shared publications
  • Rui Li

    University of Science and Technology of China

    4 shared publications
  • Tianlong Liu

    Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China

    4 shared publications
  • Adnan I Qureshi

    The Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, Missouri, USA

    3 shared publications

Latest Publications

  • Open Access

    Endovascular thrombectomy alone versus intravenous thrombolysis plus endovascular thrombectomy on acute basilar artery occlusion (ATTENTION IV): study protocol for a multicentre randomised controlled trial

    by Rui Li, Thanh N Nguyen, Chunrong Tao, Jun Sun, Pengfei Xu, Cong Luo, Li Wang, Tianlong Liu, Jianlong Song, Xiaozhong Jing, et al.

    Introduction: The DEVT and DIRECT-MT trials showed that endovascular thrombectomy (EVT) alone is non-inferior to intravenous thrombolysis (IVT) followed by EVT in achieving 90-day functional independence for stroke patients with large-vessel occlusion (LVO). However, it is unclear whether EVT alone is non-inferior to IVT followed by EVT among patients with acute basilar artery occlusion (BAO). Therefore, additional studies are needed to explore the potential benefits of EVT alone in these patients. Methods and analysis: The ATTENTION IV trial is a prospective, multicentre, non-inferiority, blinded endpoint assessment, randomised controlled clinical trial to assess the effect of EVT alone compared with IVT plus EVT in acute BAO patients within 4.5 hours of symptom onset. Patients will be randomised in a 1:1 ratio to either the EVT-alone group or the IVT-plus-EVT group. A score of 0–2 on the 90-day modified Rankin Scale (mRS) was designated as the primary outcome for this study. Primary analysis will follow the intention-to-treat principle with a 15% non-inferiority margin. Secondary outcomes encompass functional status (mRS shift, excellent/good/fair outcomes), quality of life, early neurological recovery and radiological outcomes alongside safety endpoints of intracerebral haemorrhage and mortality. Ethics and dissemination: This study has been approved by the Ethics Committee of the First Affiliated Hospital of the University of Science and Technology of China (2023KY-055) and will be conducted following the Declaration of Helsinki. Study results will be published in peer-reviewed academic journals. Trial registration number: ClinicalTrials.gov ( NCT05827042 ).

  • Open Access

    Extending the time window for intravenous tenecteplase in patients with distal medium vessel occlusions stroke: study protocol and rationale

    by Xiaozhong Jing, Raul G Nogueira, Thanh Nguyen, Mohamad Abdalkader, Abdullah M Al-Qudah, Chunrong Tao, Rui Li, Jun Sun, Yuyou Zhu, Li Wang, et al.

    Background: The TRACE III trial showed that for patients with large arterial occlusion presenting 4.5–24 hours of symptom occurrence and a salvageable penumbra on perfusion imaging, intravenous tenecteplase (TNK) thrombolysis is safe and can significantly improve patient outcomes in cases where endovascular thrombectomy is not feasible. However, it is currently unknown whether intravenous TNK thrombolysis beyond 4.5 hours can improve the outcomes of subjects with distal medium vessel occlusion (MeVO). Objective: To determine the safety and effectiveness of extended window TNK thrombolysis for MeVO stroke. Methods and design: Extending the Time Window for Intravenous TNK in Patients with Distal Medium Vessel Occlusions Stroke (TNK-MeVO) is a prospective, randomised, controlled, multicentre and open-label study with blinded outcome assessment. Up to 560 eligible subjects will be randomised 1:1 to receive TNK thrombolysis or standard medical management in over 40 comprehensive stroke centres across China. Outcomes: The primary endpoint is the rates of modified Rankin Scale score of 0–1 at 90 days. Safety endpoints include symptomatic intracerebral haemorrhage within 24 hours and mortality at 90 days. Conclusions: TNK-MeVO trial is designed to provide robust evidence on whether TNK thrombolysis is safe and effective for acute MeVO stroke presenting 4.5–24 hours of symptom onset. Trial registration number: NCT06559436 .

  • Open Access

    Intravenous tenecteplase before endovascular thrombectomy in patients with acute basilar artery occlusion within 4.5–24 hours: study protocol and rationale

    by Rui Li, Thanh Nguyen, Chunrong Tao, Jun Sun, Pengfei Xu, Cong Luo, Li Wang, Tianlong Liu, Jianlong Song, Xiaozhong Jing, et al.

    Background and purpose: One clinical trial demonstrated the beneficial effect of intravenous tenecteplase for large vessel occlusion patients not undergoing endovascular thrombectomy (EVT) within 4.5–24 hours. However, for those with acute basilar artery occlusion (BAO) presenting beyond the 4.5-hour therapeutic window, it remains unknown whether intravenous thrombolysis before EVT is beneficial. This study hypothesised that treatment of acute BAO patients with intravenous tenecteplase before EVT will result in better clinical outcomes vs EVT alone within 4.5–24 hours. Methods and design: ATTENTION LATE is a prospective, multicentre, randomised, controlled, open-label trial with blinded endpoint assessment. This study will enrol patients with acute BAO who present within 4.5–24 hours of symptom onset. These patients will be randomised 1:1 to either intravenous tenecteplase bridging to EVT or EVT alone. Study outcomes: A score of 0–2 on the modified Rankin Scale at 90 days will serve as the primary endpoint. Discussion: The ATTENTION LATE trial evaluates whether administering intravenous tenecteplase is safe and effective for acute BAO patients prior to EVT beyond the 4.5-hour time frame. This trial could establish the basis for expanding the eligible patient population to receive intravenous thrombolysis and extending the time window for acute BAO. Trial registration number: NCT05701956 .


  • Open Access

    Intra-arterial tenecteplase following endovascular therapy in patients with acute posterior circulation arterial occlusion: study protocol and rationale

    by Chunrong Tao, Rui Li, Jun Sun, Yuyou Zhu, Li Wang, Chao Zhang, Tianlong Liu, Jianlong Song, Adnan I Qureshi, Mohamad Abdalkader, et al.

    Background Recently, a randomized controlled trial showed a beneficial effect of intra-arterial thrombolysis following successful endovascular thrombectomy (EVT) in patients with acute ischemic stroke due to large vessel occlusion in the anterior circulation. Due to differences in response to thrombolytics in occlusion of the posterior circulation, the purpose of ATTENTION IA is to explore the adjunct benefit of intra-arterial thrombolysis after successful recanalization in patients presenting with large and medium vessel occlusion of the posterior circulation. Methods ATTENTION-IA is an investigator-initiated, multicenter, prospective, randomized clinical trial with open-label treatment and blinded endpoint assessment (PROBE). After achieving successful recanalization (expanded Thrombolysis In Cerebral Infarction (eTICI) 2b-3) of an occlusion of the vertebral, basilar, or posterior cerebral artery, patients will be randomized 1:1 to receive intra-arterial tenecteplase or standard of care. The primary effect parameter is a modified Rankin Score of 0–1 at day 90. Results The trial recently completed enrollment, and data collection/verification is ongoing. The final results will be made available on completion of enrollment and follow-up. Conclusions ATTENTION-IA will provide definitive evidence for the efficacy and safety of adjunct intra-arterial tenecteplase after successful EVT in patients with an acute posterior circulation arterial occlusion stroke presenting within 24 hours of symptom onset. Trial registration ClinicalTrials.gov NCT05684172.